arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXT
$7.29 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
81 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $98.2M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -7.8% ↗
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 4.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Jul 2, 2026.

81-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-1.99M
↓ -156.2% —
FCF / Share Free cash flow per share
$-0.12
↑ +28.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns →
14
Financial Health ↑
6
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 21 years · 81 quarters